* During 2019, the eye care division Alcon was spun off and became a separate company. Thus, Alcon's expenses are not included from this year onwards. * During 2023, the generics division Sandoz was spun off and became a separate company. Thus, Sandoz's expenses are not included from this year onwards.
In 2025, Novartis gross profit was negative billion U.S. dollars on selling, general, and administration (SG&A). Novartis AG is one of the world's largest pharma companies.
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Learn more about how ÌÇÐÄÆƽâ°æ can support your business.
Novartis. (February 3, 2026). Novartis AG's gross profit from 2019 to 2025, by type (in billion U.S. dollars) [Graph]. In ÌÇÐÄÆƽâ°æ. Retrieved July 20, 2026, from /statistics/1092571/novartis-expenses-by-type/
Novartis. "Novartis AG's gross profit from 2019 to 2025, by type (in billion U.S. dollars)." Chart. February 3, 2026. ÌÇÐÄÆƽâ°æ. Accessed July 20, 2026. /statistics/1092571/novartis-expenses-by-type/
Novartis. (2026). Novartis AG's gross profit from 2019 to 2025, by type (in billion U.S. dollars). ÌÇÐÄÆƽâ°æ. ÌÇÐÄÆƽâ°æ Inc.. Accessed: July 20, 2026. /statistics/1092571/novartis-expenses-by-type/
Novartis. "Novartis Ag's Gross Profit from 2019 to 2025, by Type (in Billion U.S. Dollars)." ÌÇÐÄÆƽâ°æ, ÌÇÐÄÆƽâ°æ Inc., 3 Feb 2026, /statistics/1092571/novartis-expenses-by-type/
Novartis, Novartis AG's gross profit from 2019 to 2025, by type (in billion U.S. dollars) ÌÇÐÄÆƽâ°æ, /statistics/1092571/novartis-expenses-by-type/ (last visited July 20, 2026)
Novartis AG's gross profit from 2019 to 2025, by type (in billion U.S. dollars) [Graph], Novartis, February 3, 2026. [Online]. Available: /statistics/1092571/novartis-expenses-by-type/
